The great debate at "immunotherapy Bridge 2018", Naples, November 29th, 2018

Paolo A. Ascierto, Lisa H. Butterfield, Sandra Demaria, Robert L. Ferris, Gordon J. Freeman, Roger S. Lo, Alberto Mantovani, Paul Nathan, Omid Hamid, Katerina Politi, Igor Puzanov

Research output: Contribution to journalReview articlepeer-review


As part of the 2018 Immunotherapy Bridge congress (November 28-29, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on four topical clinical issues in immunotherapy today. These were: the relative importance of adaptive versus innate immunity in the anti-cancer immune response; the merits of combination versus sequential immunotherapy regimens in the treatment of cancer; the advantages and disadvantages of murine models of cancer versus humans in order to evaluate immunotherapy; and whether or not mechanisms of resistance to immunotherapy differ between different cancers. Discussion of these important topics are summarised in this report.

Original languageEnglish
Article number221
JournalJournal for ImmunoTherapy of Cancer
Issue number1
Publication statusPublished - Aug 15 2019


  • Anti-CTLA-4
  • Anti-PD-1
  • Cancer
  • Combination therapy
  • Immunity
  • Immunotherapy
  • Treatment resistance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'The great debate at "immunotherapy Bridge 2018", Naples, November 29th, 2018'. Together they form a unique fingerprint.

Cite this